Company intelligence / Profile preview
Mirabilis Therapeutics
Maastricht, Limburg, Netherlandsmirabilis-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Mirabilis Therapeutics is a biopharmaceutical company specializing in the development of microRNA-based therapies for cardiovascular diseases. The company's core technology focuses on identifying and modulating specific microRNAs that drive disease progression in the heart. Its lead program, MRB-001, is an antisense oligonucleotide targeting miR-199a-3p, which has been shown to play a critical role in cardiac hypertrophy and heart failure. Mirabilis was founded as a spin-off from Maastricht University, building on the pioneering research of Professor Leon de Windt. The company has previously entered into strategic collaborations, including an option agreement with Servier, to advance its therapeutic pipeline toward clinical validation.
- Therapeutic areas
- Cardiovascular
- Modalities
- Antisense oligonucleotideRNA therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Servier
Beyond the preview
Go deeper on Mirabilis Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mirabilis Therapeutics.